Immunity in bronchiectasis: immunoglobulin replacement therapy

M. Vendrell Relat (Girona, Spain)

Source: Annual Congress 2009 - An update on bronchiectasis
Session: An update on bronchiectasis
Session type: Symposium
Number: 334

Slide presentationMultimedia files

Rating: 4
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Vendrell Relat (Girona, Spain). Immunity in bronchiectasis: immunoglobulin replacement therapy. Annual Congress 2009 - An update on bronchiectasis

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pulmonary immunoglobulin E levels and the response to anti-immunoglobulin E antibody therapy in paediatric severe therapy resistant asthma
Source: Annual Congress 2012 - Treating childhood asthma
Year: 2012




Late Breaking Abstract - The respiratory tract of patients with antibody deficiency on immunoglobulin replacement is characterised by inflammation and dysbiosis despite adequate levels of sputum IgG
Source: Virtual Congress 2021 – Bronchiectasis heterogeneity: assessing the endotypes
Year: 2021



Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016


Efficacy of augmentation therapy for emphysema associated with alpha1-antitrypsin deficiency: enough is enough
Source: Eur Respir J 2016; 47: 35-38
Year: 2016


Pattern of bronchial colonization and inflammatory response in patients with bronchiectasis and immunoglobulin deficiency (Igdef)
Source: Eur Respir J 2001; 18: Suppl. 33, 466s
Year: 2001

Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids
Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease
Year: 2009

Systemic corticosteroid and inhalation corticosteroid therapy are associated with nontuberculous mycobacterial pulmonary disease
Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology
Year: 2015


Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021


Alternating inhaled antibiotic therapy in CF: A single center analysis
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015


Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis
Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases
Year: 2020


Serum level directed itraconazole therapy in allergic bronchopulmonary aspergillosis
Source: International Congress 2016 – Molecular immunology of the lung
Year: 2016



Oral human serum immunoglobulin for norovirus diarrhea in pulmonary transplant patients
Source: Annual Congress 2013 –Clinical studies in lung transplantation
Year: 2013


Immunoglobulin G subclass deficiency in adult patients with chronic obstructive lung diseases
Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections
Year: 2014


Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013


Airway obstruction in sarcoidosis: mechanisms and response to therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 433s
Year: 2002

Prolonged oral corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA) treatment does not increase pseudomonas aeruginosa risk
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015

The real world effectiveness and effect on adherence with inhaled asthma therapy of 1 year of Severe Asthma Monoclonal Antibody Treatment
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020


Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis
Source: ERJ Open Res, 3 (3) 00016-2017; 10.1183/23120541.00016-2017
Year: 2017



Specific IgG antibodies in chronic hypersensitivity pneumonitis
Source: International Congress 2015 – IIPs: orphan
Year: 2015